Luxeptinib (CG-806) is a novel pan-FLT3/pan-BTK inhibitor that is administered orally. It exhibits potent and reversible inhibition of these enzymes, acting through a non-covalent mechanism. Luxeptinib effectively induces cell cycle arrest, apoptosis, or autophagy in acute myeloid leukemia cells [1][2][3][4].
Molekulargewicht:
495.43
CAS Nummer:
[1616428-23-9]
Formel:
C25H17F4N5O2
Target-Kategorie:
FLT|||Others|||BTK|||Apoptosis
T37085
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten